Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
According to the press release, the expansion marks a significant step in Lantern’s mission to transform drug development through artificial intelligence. The LQM is designed to be user-friendly, allowing researchers to input a molecular structure and receive a detailed developability profile instantly. This capability could reduce the time and cost associated with early-stage drug discovery by identifying promising candidates more efficiently.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern’s withZeta.ai platform, a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The expansion of predictBBB into an LQM underscores Lantern’s commitment to democratizing access to advanced computational tools for drug discovery. By providing a web-based platform that delivers rapid analysis, the company aims to empower researchers worldwide to make data-driven decisions earlier in the development process. The implications of this announcement include potentially faster identification of drug candidates, reduced reliance on costly experimental methods, and greater collaboration across the biomedical research community.
For more information, visit the full press release at https://ibn.fm/XqWld. About Lantern Pharma Inc.: Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. For the latest news and updates relating to LTRN, visit the company’s newsroom at https://ibn.fm/LTRN.
